Michael Gilman is the CEO of a biotech startup showing early progress on a technology that was once thought to be impossible, but which may herald an entirely new class of oral medicines.

Almost every pill people take works by altering the activity of a protein. Something like 99 percent of medicines, in fact, are targeted against disease-causing proteins. That’s fine, as long as those small-molecule drugs — the chemicals that are made into pills — are able to lock into the nooks and crannies of disease-causing proteins. The problem is that a vast majority of proteins, something like 85 percent, don’t have these nooks and crannies. And that means they are undruggable with conventional medicines.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Your daily dose of news in health and medicine

Privacy Policy